Skip to search formSkip to main contentSkip to account menu

RPL 554

Known as: RPL-554, RPL554 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
RPL554 (Dual PDE3/4 Enzyme Inhibitor): Baseline Airway Reversibility Impacts Immediate Bronchodilation, in Contrast to Progressive Symptom Improvement
2018
2018
Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study
Introduction: RPL554 is an inhaled dual PDE3/4 inhibitor that showed bronchodilator and anti-inflammatory effects in prior… 
2017
2017
Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle
  • 2017
  • Corpus ID: 62804213
6,794,391 B2* 9/2004 Oxford ................ CO7D 471,04 (71) Applicant: VERONA PHARMA PLC, Cardiff 514,211.12 (GB) 7,105,663 B2… 
2016
2016
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients
RPL554 has previously been shown to be a well tolerated bronchodilator, bronchoprotective, & anti-inflammatory agent in clinical… 
2016
2016
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD…
RPL554 is a novel, well tolerated dual PDE3/4 inhibitor with significant bronchodilator activity in COPD & asthma together with… 
2016
2016
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects
RPL554 has bronchodilator, bronchoprotective, & anti-inflammatory effects. We investigated the dose-ranging effects & safety of a… 
2015
2015
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in…
Introduction: RPL554 causes clinically effective bronchodilation in asthma and COPD (Franciosi, L.G et al. Lancet Respir Med 2013… 
2014
2014
Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi
Background : The acute relaxant synergistic interaction between RPL554 and anticholinergic agents has been recently proved on… 
2014
2014
Interaction between RPL554 and glycopyrronium bromide in small human airways
Background :The relaxant synergistic interaction between RPL554 and anticholinergic agents has been recently proved on human… 
2013
2013
A combined phase I/IIa study of the safety, bronchodilator and bronchoprotective effects of nebulized RPL554, a dual PDE3/4-inhibitor, in healthy subjects and asthmatics
Methods The safety of RPL554 0.003 and 0.009 mg/kg was evaluated in 18 healthy males (age 18-41 years; weight 58-90 kg; height… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)